Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BG9928 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| BG9928 | DRUG | Oral 75 mg single dose |
Inclusion Criteria: * Must be between the ages of 18 and 75, inclusive. * Must have a Body Mass Index (BMI) between 19 kg/m2 and 36 kg/m2, inclusive. The following criteria apply only to subjects enrolled into Groups 1 and 2 (mild or moderate hepatic impairment): * Must have stable hepatic diseas...
BG9928 is an investigational small molecule being studied for use in hepatic impairment. It is being developed by Biogen Inc. (BIIB) and is currently in Phase 1 clinical development. The drug is intended for patients with compromised liver function, though its specific therapeutic application has not been fully established.
BG9928 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker BIIB. Biogen is conducting clinical research on this small molecule for hepatic impairment, with the drug currently in Phase 1 development.
BG9928 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for hepatic impairment, and its Phase 1 trial has been completed.
BG9928 has one completed clinical trial, identified as NCT00858156, titled "BG9928 in Subjects With Hepatic Impairment." This Phase 1 study enrolled 23 participants in the United States, including healthy volunteers, and evaluated the drug's effects in individuals with hepatic impairment.
BG9928 is a distinct investigational small molecule developed by Biogen Inc. for hepatic impairment. No alternative names for this drug have been reported in clinical trial records. It is currently in Phase 1 development and is not yet approved for any use.